Tetsuji Yamaguchi1, Yasumasa Takii, Satoshi Maruyama. 1. Department of Surgery, Niigata Cancer Center Hospital, 2-15-3 Kawagishicho, Chuo-ku, Niigata, 951-8566, Japan, tetsuji-yama@blue.ocn.ne.jp.
Abstract
PURPOSES: Recently, the serum p53 antibody (S-p53Ab) has been used widely in clinical practice as a tumor marker for colorectal cancer (CRC). However, no large-scale studies have examined the usefulness of serial measurements of S-p53Ab or have established the relationship of this parameter with the clinicopathological factors of CRC. METHODS: An ELISA for S-p53Ab was performed for 1384 primary CRC patients, and the results were categorized by the clinicopathological factors. RESULTS: The S-p53Ab positivity rate was 24.1 %, and was significantly higher in Stage III-IV than in Stage 0-II cases. However, no relationship was seen with the serum carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA19-9) levels. The addition of the S-p53Ab assay to the CEA and CA19-9 measurements increased the overall diagnostic sensitivity to 50.9 % (CEA and/or CA19-9: 37.3 %). In patients who had undergone complete resection, S-p53Ab positivity was associated with a decrease in the relapse-free survival (p = 0.012), but it was not independent prognostic indicator. S-p53Ab positivity had no influence on the cancer-specific survival. CONCLUSIONS: The S-p53Ab positivity rate was higher than the positivity rates for CEA and/or CA19-9 in Stage 0-I CRC patients. Combining the use of the three tumor marker tests is a potentially effective method for detecting even early-stage CRC.
PURPOSES: Recently, the serum p53 antibody (S-p53Ab) has been used widely in clinical practice as a tumor marker for colorectal cancer (CRC). However, no large-scale studies have examined the usefulness of serial measurements of S-p53Ab or have established the relationship of this parameter with the clinicopathological factors of CRC. METHODS: An ELISA for S-p53Ab was performed for 1384 primary CRC patients, and the results were categorized by the clinicopathological factors. RESULTS: The S-p53Ab positivity rate was 24.1 %, and was significantly higher in Stage III-IV than in Stage 0-II cases. However, no relationship was seen with the serum carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA19-9) levels. The addition of the S-p53Ab assay to the CEA and CA19-9 measurements increased the overall diagnostic sensitivity to 50.9 % (CEA and/or CA19-9: 37.3 %). In patients who had undergone complete resection, S-p53Ab positivity was associated with a decrease in the relapse-free survival (p = 0.012), but it was not independent prognostic indicator. S-p53Ab positivity had no influence on the cancer-specific survival. CONCLUSIONS: The S-p53Ab positivity rate was higher than the positivity rates for CEA and/or CA19-9 in Stage 0-I CRC patients. Combining the use of the three tumor marker tests is a potentially effective method for detecting even early-stage CRC.
Authors: R Tang; M C Ko; J Y Wang; C R Changchien; H H Chen; J S Chen; K C Hsu; J M Chiang; L L Hsieh Journal: Int J Cancer Date: 2001-12-15 Impact factor: 7.396
Authors: P Würl; F Weigmann; A Meye; M Fittkau; U Rose; D Berger; F W Rath; H Dralle; H Taubert Journal: Scand J Gastroenterol Date: 1997-11 Impact factor: 2.423
Authors: G Shiota; M Ishida; N Noguchi; K Oyama; Y Takano; M Okubo; S Katayama; Y Tomie; K Harada; K Hori; K Ashida; Y Kishimoto; A Hosoda; T Suou; T Kanbe; K Tanaka; K Nosaka; O Tanida; H Kojo; K Miura; H Ito; N Kaibara; H Kawasaki Journal: Dig Dis Sci Date: 2000-01 Impact factor: 3.199
Authors: H Shimada; K Nakajima; T Ochiai; Y Koide; S I Okazumi; H Matsubara; A Takeda; Y Miyazawa; M Arima; K Isono Journal: Oncol Rep Date: 1998 Jul-Aug Impact factor: 3.906
Authors: G Shiota; Y Kishimoto; A Suyama; M Okubo; S Katayama; K Harada; M Ishida; K Hori; T Suou; H Kawasaki Journal: J Hepatol Date: 1997-10 Impact factor: 25.083
Authors: Thomas V Guy; Alexandra M Terry; Holly A Bolton; David G Hancock; Erhua Zhu; Robert Brink; Helen M McGuire; Elena Shklovskaya; Barbara Fazekas de St. Groth Journal: Oncotarget Date: 2016-05-24